Charco Neurotech develops non-invasive wearable devices that employ neuromodulation technology to manage chronic pain and enhance mobility in patients with neurological disorders. Their products deliver measurable pain relief and improved functional outcomes for individuals with conditions such as Parkinson's disease and multiple sclerosis.
Funding
$11.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Parkinson's disease patients often experience motor-related symptoms such as slowness, stiffness, rigidity, and freezing of gait, which significantly impact their mobility and overall quality of life. Current treatments may not fully alleviate these symptoms, and patients require solutions to manage their condition and improve movement control.
Solution
Charco Neurotech offers the CUE Device, a non-invasive wearable medical device designed to improve movement and quality of life for individuals with Parkinson's disease. The CUE Device utilizes pulsed cueing and high-frequency focused vibrotactile stimulation to alleviate motor symptoms. By delivering gentle vibratory stimulus to the peripheral nervous system, the device modulates sensory processing, easing stiffness and slowness. The CUE app allows users to customize stimulation settings, set medication reminders via discreet vibrations, and track symptoms to help manage their condition.
Target Audience
The primary target audience includes individuals diagnosed with Parkinson's disease seeking non-invasive solutions to manage motor-related symptoms and improve their overall quality of life.
Features
- Non-invasive wearable device utilizing pulsed cueing and high-frequency focused vibrotactile stimulation
- Customizable stimulation settings via the CUE app for personalized treatment
- Discreet medication reminders through gentle vibrations
- Symptom tracking within the CUE app to monitor mood, movement, and other symptoms over time
- Compact and discreet design for comfortable wear under clothing
- Clinically significant improvements in MDS-UPDRS scores reported in pilot tests